Low doses of IL-4 injected perilymphatically in tumor-bearing mice inhibit the growth of poorly and apparently nonimmunogenic tumors and induce a tumor-specific immune memory.
Open Access
- 1 November 1990
- journal article
- research article
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 145 (9) , 3136-3143
- https://doi.org/10.4049/jimmunol.145.9.3136
Abstract
The ability of rIL-4 to trigger host reactivity against both a chemically induced fibrosarcoma (CE-2) and a spontaneous adenocarcinoma (TS/A) of BALB/c mice was studied. Daily local s.c. administration around tumor draining lymph nodes of 10 injections of progressive amounts (0.00001 to 1000 pg/day) of rIL-4 induced appreciable inhibition of the growth of both tumors after a dose-response survival curve peaking at 0.1 pg/day. Inasmuch as rIL-4 has no direct antitumor activity, as shown by in vitro tests, host immune reactivity plays a fundamental role in this lymphokine activated tumor inhibition (LATI). LATI, in fact, is abolished when recipient mice are sublethally irradiated or treated with cyclosporin A, or when the reactivity of CD4+ lymphocytes is suppressed, whereas it is not affected by anti-asialo GM1 antibody. The morphologic data show that rIL-4 LATI rests on the recruitment of several cell reaction mechanisms, among which those that are nonspecific seem to predominate. rIL-4 LATI also leads to a state of long lasting and specific immune memory: the growth of a second contralateral tumor challenge is significantly impaired after LATI. This immune memory takes place after LATI of both the poorly immunogenic CE-2 fibrosarcoma and the TS/A adenocarcinoma, previously classed as nonimmunogenic on the basis of immunization-protection tests. In the latter case, adoptive transfer experiments show that Thy-1+ lymphocytes and, in particular, the CD4 cell-depleted T lymphocyte subpopulation, are responsible for the immune memory. Finally, the ability of rIL-4 to trigger LATI is greater than that of the most effective doses of rIL-2, rIL-1 beta, and IFN-gamma, whereas its association with rIL-1 beta induces a more effective immune memory.This publication has 25 references indexed in Scilit:
- Inhibition of Interferon-Gamma May Suppress Allograft Reactivity by T Lymphocytes in Vitro and in VivoScience, 1985
- Therapy of disseminated murine leukemia with cyclophosphamide and immune Lyt-1+,2- T cells. Tumor eradication does not require participation of cytotoxic T cells.The Journal of Experimental Medicine, 1985
- Lymphokine-activated tumor inhibition in vivo. I. The local administration of interleukin 2 triggers nonreactive lymphocytes from tumor-bearing mice to inhibit tumor growth.The Journal of Immunology, 1985
- Acquired immunological tolerance of foreign cells is impaired by recombinant interleukin 2 or vitamin A acetate.Proceedings of the National Academy of Sciences, 1985
- Antibodies to interleukin 2. Effects on immune responses in vitro and in vivo.The Journal of Experimental Medicine, 1984
- In vitro reeducated T helper cells from sarcoma-bearing mice inhibit sarcoma growth in vivo.The Journal of Immunology, 1984
- TS/A: a new metastasizing cell line from a BALB/c spontaneous mammary adenocarcinomaClinical & Experimental Metastasis, 1983
- In vitro detection of cell‐mediated immunity to individual tumor‐specific antigens of chemically induced BALB/c fibrosarcomasInternational Journal of Cancer, 1983
- EOSINOPHIL INFILTRATION OF HUMAN COLONIC CARCINOMAS AS A PROGNOSTIC INDICATOR1983
- Immune recognition of tumor cells in vivo. I. Role of H‐2 gene products in T lymphocyte activation against minor histocompatibility antigens displayed by adenocarcinoma cellsEuropean Journal of Immunology, 1982